A detailed history of Pinnacle Associates LTD transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Pinnacle Associates LTD holds 103,081 shares of PRTA stock, worth $1.46 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
103,081
Previous 125,747 18.03%
Holding current value
$1.46 Million
Previous $2.1 Million 32.14%
% of portfolio
0.02%
Previous 0.03%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$11.95 - $18.35 $270,858 - $415,921
-22,666 Reduced 18.03%
103,081 $1.43 Million
Q3 2024

Oct 25, 2024

BUY
$16.73 - $24.79 $47,630 - $70,577
2,847 Added 2.32%
125,747 $2.1 Million
Q2 2024

Jul 30, 2024

SELL
$19.54 - $26.15 $46,192 - $61,818
-2,364 Reduced 1.89%
122,900 $2.54 Million
Q1 2024

Apr 26, 2024

SELL
$24.75 - $40.66 $11,954 - $19,638
-483 Reduced 0.38%
125,264 $3.1 Million
Q4 2023

Jan 19, 2024

BUY
$32.31 - $52.32 $23,941 - $38,769
741 Added 0.59%
125,747 $4.57 Million
Q3 2023

Oct 23, 2023

SELL
$47.3 - $70.6 $257,926 - $384,981
-5,453 Reduced 4.18%
125,006 $6.03 Million
Q2 2023

Jul 26, 2023

SELL
$48.26 - $78.59 $232,709 - $378,960
-4,822 Reduced 3.56%
130,459 $8.91 Million
Q1 2023

May 04, 2023

SELL
$46.97 - $58.27 $107,561 - $133,438
-2,290 Reduced 1.66%
135,281 $6.56 Million
Q4 2022

Jan 31, 2023

BUY
$52.05 - $65.0 $10,410 - $13,000
200 Added 0.15%
137,571 $8.29 Million
Q4 2022

Jan 25, 2023

SELL
$52.05 - $65.0 $141,836 - $177,125
-2,725 Reduced 1.95%
137,371 $0
Q3 2022

Oct 31, 2022

SELL
$25.16 - $60.63 $108,942 - $262,527
-4,330 Reduced 3.0%
140,096 $8.49 Million
Q2 2022

Aug 02, 2022

SELL
$22.73 - $39.98 $9,273 - $16,311
-408 Reduced 0.28%
144,426 $3.92 Million
Q1 2022

May 05, 2022

SELL
$30.27 - $49.22 $193,122 - $314,023
-6,380 Reduced 4.22%
144,834 $5.3 Million
Q4 2021

Feb 02, 2022

SELL
$42.11 - $73.26 $23,665 - $41,172
-562 Reduced 0.37%
151,214 $7.47 Million
Q3 2021

Oct 19, 2021

SELL
$48.2 - $78.89 $2.61 Million - $4.27 Million
-54,142 Reduced 26.29%
151,776 $10.8 Million
Q2 2021

Aug 02, 2021

SELL
$21.63 - $57.65 $1.59 Million - $4.25 Million
-73,642 Reduced 26.34%
205,918 $10.6 Million
Q1 2021

May 12, 2021

SELL
$11.0 - $28.24 $323,620 - $830,820
-29,420 Reduced 9.52%
279,560 $7.02 Million
Q4 2020

Jan 26, 2021

SELL
$10.12 - $13.94 $222,943 - $307,098
-22,030 Reduced 6.66%
308,980 $3.71 Million
Q3 2020

Oct 23, 2020

SELL
$9.93 - $13.47 $118,176 - $160,306
-11,901 Reduced 3.47%
331,010 $3.31 Million
Q2 2020

Aug 14, 2020

SELL
$9.56 - $12.51 $57,790 - $75,622
-6,045 Reduced 1.73%
342,911 $3.59 Million
Q1 2020

May 13, 2020

SELL
$7.54 - $15.77 $383,265 - $801,604
-50,831 Reduced 12.71%
348,956 $3.73 Million
Q4 2019

Feb 03, 2020

BUY
$7.48 - $17.01 $1.58 Million - $3.59 Million
211,319 Added 112.12%
399,787 $6.33 Million
Q3 2019

Nov 08, 2019

SELL
$6.89 - $10.45 $66,385 - $100,685
-9,635 Reduced 4.86%
188,468 $1.48 Million
Q2 2019

Aug 05, 2019

SELL
$8.85 - $12.49 $157,450 - $222,209
-17,791 Reduced 8.24%
198,103 $2.09 Million
Q1 2019

May 10, 2019

BUY
$10.32 - $14.49 $169,764 - $238,360
16,450 Added 8.25%
215,894 $2.62 Million
Q4 2018

Feb 05, 2019

SELL
$8.73 - $13.74 $334,498 - $526,461
-38,316 Reduced 16.12%
199,444 $2.05 Million
Q3 2018

Nov 13, 2018

SELL
$12.7 - $15.79 $473,189 - $588,319
-37,259 Reduced 13.55%
237,760 $3.11 Million
Q2 2018

Aug 08, 2018

SELL
$10.99 - $44.21 $503,946 - $2.03 Million
-45,855 Reduced 14.29%
275,019 $4.01 Million
Q1 2018

May 11, 2018

SELL
$27.95 - $45.04 $530,770 - $855,309
-18,990 Reduced 5.59%
320,874 $11.8 Million
Q4 2017

Feb 12, 2018

SELL
$35.44 - $63.76 $703,129 - $1.26 Million
-19,840 Reduced 5.52%
339,864 $12.7 Million
Q3 2017

Nov 13, 2017

SELL
$53.83 - $67.75 $518,329 - $652,364
-9,629 Reduced 2.61%
359,704 $23.3 Million
Q2 2017

Aug 09, 2017

BUY
N/A
369,333
369,333 $20 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $665M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Pinnacle Associates LTD Portfolio

Follow Pinnacle Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.